MMEA
IBB icon

Main Management ETF Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Main Management ETF Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-612,180
Closed -$78.3M – 139
2025
Q1 		$78.3M Hold
612,180
– – 3.81% 10
2024
Q4 		$80.9M Buy
612,180
+18,810
+3% +$2.64M 3.67% 10
2024
Q3 		$86.4M Buy
593,370
+14,535
+3% +$2.1M 4.1% 8
2024
Q2 		$79.5M Buy
578,835
+14,535
+3% +$1.94M 3.97% 9
2024
Q1 		$77.4M Buy
564,300
+18,810
+3% +$2.57M 4.09% 10
2023
Q4 		$74.1M Buy
+545,490
New +$66.6M 4.35% 9
2022
Q4 		– Sell
-177,480
Closed -$20.8M – 35
2022
Q3 		$20.8M Buy
177,480
+1,440
+0.8% +$179K 2.38% 15
2022
Q2 		$20.7M Sell
176,040
-360
-0.2% -$42.7K 2.3% 14
2022
Q1 		$23M Buy
176,400
+1,080
+0.6% +$141K 2.14% 14
2021
Q4 		$26.8M Buy
175,320
+9,000
+5% +$1.39M 2.35% 14
2021
Q3 		$26.9M Buy
166,320
+7,560
+5% +$1.27M 2.72% 14
2021
Q2 		$26M Buy
158,760
+8,280
+6% +$1.28M 2.71% 14
2021
Q1 		$22.7M Buy
150,480
+28,050
+23% +$4.46M 2.68% 14
2020
Q4 		$18.5M Sell
122,430
-330
-0.3% -$47.2K 2.9% 14
2020
Q3 		$16.6M Sell
122,760
-3,300
-3% -$448K 2.93% 13
2020
Q2 		$17.2M Buy
126,060
+5,610
+5% +$715K 3.25% 12
2020
Q1 		$13M Sell
120,450
-330
-0.3% -$38K 3.1% 11
2019
Q4 		$14.6M Buy
120,780
+5,280
+5% +$589K 2.82% 12
2019
Q3 		$11.5M Sell
115,500
-84,300
-42% -$8.82M 2.5% 12
2019
Q2 		$21.8M Buy
199,800
+12,000
+6% +$1.28M 5.02% 10
2019
Q1 		$21M Buy
187,800
+10,200
+6% +$1.12M 4.87% 10
2018
Q4 		$17.1M Buy
177,600
+10,200
+6% +$1.08M 4.79% 9
2018
Q3 		$20.4M Buy
167,400
+19,800
+13% +$2.33M 5.14% 8
2018
Q2 		$16.2M Buy
147,600
+22,200
+18% +$2.37M 4.83% 9
2018
Q1 		$13.4M Buy
125,400
+20,400
+19% +$2.26M 4.74% 10
2017
Q4 		$11.2M Buy
+105,000
New +$11.2M 4.79% 9

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Main Management ETF Advisors's IBB Position: Q2 2025 in Review

Main Management ETF Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2025, closing a stake of 612,180 shares — an estimated $78.3M sold.

Main Management ETF Advisors first reported a position in IBB in Q4 2017 and held it in 26 quarters. The position peaked at $86.4M in Q3 2024. 797 funds tracked by Wall St. Rank hold IBB as of Q2 2025.

  • Main Management ETF Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2025 after selling out during the quarter.
  • Main Management ETF Advisors sold 612,180 iShares Biotechnology ETF shares in Q2 2025, an estimated $78.3M.
  • Main Management ETF Advisors first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 26 quarters.
  • Main Management ETF Advisors's iShares Biotechnology ETF position peaked at $86.4M in Q3 2024.
  • 797 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2025.

Based on Main Management ETF Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.